Publication:
Non-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients.

dc.contributor.authorFerrer, Ricard
dc.contributor.authorMateu, Xavier
dc.contributor.authorMaseda, Emilio
dc.contributor.authorYébenes, Juan Carlos
dc.contributor.authorAldecoa, César
dc.contributor.authorDe Haro, Candelaria
dc.contributor.authorRuiz-Rodriguez, Juan Carlos
dc.contributor.authorGarnacho-Montero, José
dc.date.accessioned2023-01-25T10:01:51Z
dc.date.available2023-01-25T10:01:51Z
dc.date.issued2017-12-08
dc.description.abstractEffective resuscitation with human albumin solutions is achieved with less fluid than with crystalloid solutions. However, the role of albumin in today's critical care unit is also linked to its multiple pharmacological effects. Areas covered: The potential clinical benefits of albumin in select populations of critically ill patients like sepsis seem related to immunomodulatory and anti-inflammatory effects, antibiotic transportation and endothelial stabilization. Albumin transports many drugs used in critically ill patients. Such binding to albumin is frequently lessened in critically ill patients with hypoalbuminemia. These changes could result in sub-optimal treatment. Albumin has immunomodulatory capacity by binding several bacterial products. Albumin also influences vascular integrity, contributing to the maintenance of the normal capillary permeability. Moreover, the albumin molecule encompasses several antioxidant properties, thereby significantly reducing re-oxygenation injury, which is especially important in sepsis. In fact, most studies of albumin administration are a combination of a degree of resuscitation with a degree of maintenance or supplementation of albumin. Expert commentary: The potential clinical benefits of the use of albumin in selected critically ill patients such as sepsis seem related to its immunomodulatory and anti-inflammatory effects, antioxidant properties, antibiotic transportation and endothelial stabilization. Additional studies are warranted to further elucidate the underlying physiologic and molecular rationale.
dc.identifier.doi10.1080/17512433.2018.1412827
dc.identifier.essn1751-2441
dc.identifier.pmid29219627
dc.identifier.unpaywallURLhttp://repositori.upf.edu/bitstream/10230/35723/1/ferrer-erf-nono.pdf
dc.identifier.urihttp://hdl.handle.net/10668/11888
dc.issue.number2
dc.journal.titleExpert review of clinical pharmacology
dc.journal.titleabbreviationExpert Rev Clin Pharmacol
dc.language.isoen
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen Macarena
dc.page.number125-137
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rights.accessRightsopen access
dc.subjectAlbumin
dc.subjectantioxidation
dc.subjectcritical care
dc.subjectdrug transportation
dc.subjectendothelium
dc.subjectimmunomodulation
dc.subjectsepsis
dc.subject.meshAnimals
dc.subject.meshCritical Illness
dc.subject.meshCrystalloid Solutions
dc.subject.meshHumans
dc.subject.meshHypoalbuminemia
dc.subject.meshIntensive Care Units
dc.subject.meshIsotonic Solutions
dc.subject.meshResuscitation
dc.subject.meshSepsis
dc.subject.meshSerum Albumin, Human
dc.titleNon-oncotic properties of albumin. A multidisciplinary vision about the implications for critically ill patients.
dc.typeresearch article
dc.type.hasVersionAM
dc.volume.number11
dspace.entity.typePublication

Files